Pharmaceuticals, Biotechnology and Life Sciences
Piramal Pharma Solutions (PPS), has invested $10 million for a new wing at the Riverview site dedicated to the production of high potency active pharmaceutical ingredients (HPAPIs) with low Occupational Exposure Levels (OELs).
Sanofi and Regeneron Pharmaceuticals said Friday a Phase 2 proof-of-concept trial evaluating the investigational IL-33 antibody REGN3500 (SAR440340) met the primary endpoint of improvement in loss of asthma control when comparing REGN3500 monotherapy to placebo.
Kansas-based KCAS, a leading bioanalytical testing laboratory for the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries, said that its Shawnee Mission site, a bioanalytical testing laboratory facility, successfully completed a U.S. Food and Drug Administration (FDA) general re-inspection conducted between June 10 and June 13, 2019. The previous inspection of KCAS took place in 2016.
Syntrix Pharmaceuticals has started its Phase 1/2 clinical trial that will combine SX-682 with KEYTRUDA, Merck’s anti-PD-1 therapy, as it dosed the first patient, it said Thursday.
Edesa Biotech may continue with its clinical investigation of potential treatment for chronic allergic contact dermatitis EB01, a novel sPLA2 inhibitor, after FDA’s approval.
Camurus will start with the Phase 3 study of once-monthly octreotide subcutaneous depot for treatment of acromegaly CAM2029.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the initiation of a clinical trial evaluating KRYSTEXXA® (pegloticase injection) in combination with methotrexate as a strategy to increase the durability of response for patients living with chronic gout refractory to conventional therapies – also known as uncontrolled gout.
ROCKVILLE, Md.–(BUSINESS WIRE)–#allergies–Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the promotion of Teri Heiland, Ph.D.…
MONTGOMERY, Ala.–(BUSINESS WIRE)–Remove the three paragraphs with headings INDICATIONS AND USAGE, PRIMARY HYPERLIPIDEMIA AND MIXED DYSLIPIDEMIA, and LIMITATIONS OF USE…
First-of-their-kind results to enhance patient experience and efficacy of Columbia Care products by further informing and personalizing treatment recommendations to…